FUNDAMENTALS · Fundamentals · SG Healthcare

Cuprina Holdings (Cayman) (CUPR) Fundamentals 2026 — Revenue Analysis | SniperIQ

Cuprina Holdings (Cayman) (CUPR) is a SG-listed Healthcare company in Biotechnology with a market capitalization of

0M, trading at
.84 on the NASDAQ. This SniperIQ fundamentals page covers Cuprina Holdings (Cayman)'s valuation, profitability (net margin -9366.8%), revenue (S$49,894 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
0M
Net Margin-9366.8%
Revenue (FY25)S$49,894

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Cuprina Holdings (Cayman)'s market cap?

Cuprina Holdings (Cayman) (CUPR) has a market capitalization of approximately

0M, trading at
.84 on the NASDAQ. Market cap moves with the live share price.

What is Cuprina Holdings (Cayman)'s P/E ratio?

Cuprina Holdings (Cayman)'s trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) runs a net profit margin of -9366.8%, a gross margin of -1.3%, and an operating margin of -9154.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Cuprina Holdings (Cayman) generate?

Cuprina Holdings (Cayman) reported revenue of S$49,894 for fiscal year 2025, with net income of -S$5M and earnings per share (EPS) of -1.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Cuprina Holdings (Cayman) pay a dividend?

Cuprina Holdings (Cayman) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Cuprina Holdings (Cayman) financially healthy?

Cuprina Holdings (Cayman) carries a debt-to-equity ratio of 0.10x and a current ratio of 2.35x, with a market beta of -1.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Cuprina Holdings (Cayman) a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cuprina Holdings (Cayman) (CUPR) the key facts are: market cap

0M, revenue S$49,894, 52-week range 1.76-76. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Cuprina Holdings (Cayman)'s full fundamentals live

Get Cuprina Holdings (Cayman)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: OSR Holdings (OSRH) fundamentals · Nexalin Technology (NXL) fundamentals · Femasys (FEMY) fundamentals · BioVie (BIVI) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons